Singapore markets closed

Avicanna Inc. (AVCNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.30060.0000 (0.00%)
As of 11:36AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3006
Open0.2900
BidN/A x N/A
AskN/A x N/A
Day's range0.2900 - 0.3006
52-week range0.1780 - 0.5320
Volume1,100
Avg. volume6,843
Market cap27.742M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Avicanna Announces Closing of Non-brokered Private Placement

    TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 5,313,959 ‎‎units of the Company (the “Units”) at a price of $0.40 per Unit for aggregate gross proceeds of approximately of $2,125,000. “We are very

  • GlobeNewswire

    Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

    The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammationTORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence (“RWE”) study using RHO Phyto br

  • Simply Wall St.

    Avicanna Full Year 2023 Earnings: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

    Avicanna ( TSE:AVCN ) Full Year 2023 Results Key Financial Results Revenue: CA$16.8m (up 315% from FY 2022). Net loss...